Figures & data
Table 1. List of discrete choice experiment studies included in the systematic literature review of patient and physician preferences; including general characteristics of the studies.
Table 2. Quality assessment of the DCE studies included in the review according to both PREFS and ISPOR quality checklists.
Table 3. Quality assessment continued.
Table 4. Identification of the most and second most important attributes for each of the 25 studies included.
Appendix A. Frequency of general characteristics of studies included by category
Appendix C. The distribution of all attributes by category for each of the 25 DCE studies included in this review
Appendix D. All efficacy-specific outcome attributes extracted from all 25 DCE studies
Appendix E. All safety-specific outcome attributes extracted from all 25 DCE studies
Appendix F. All process attributes extracted from all 25 DCE studies
Appendix G. All cost-related attributes extracted from all 25 DCE studies
Ashcroft D, Seston E, Griffiths C. Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. Br J Dermatol. 2006;155(6):1236–1241. Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol. 2007;143(9):1175–1179. Hauber AB, Gonzalez JM, Schenkel B, et al. The value to patients of reducing lesion severity in plaque psoriasis. J Dermatolog Treat. 2011;22(5):266–275. Schaarschmidt M-L, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147(11):1285–1294. Schmieder A, Schaarschmidt M-L, Umar N, et al. Comorbidities significantly impact patients’ preferences for psoriasis treatments. J Am Acad Dermatol. 2012;67(3):363–372. Umar N, Schöllgen I, Terris DD. It is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis. Patient Preference and Adherence. 2012;6:187. Schaarschmidt ML, Umar N, Schmieder A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27(2):187–198. Umar N, Schaarschmidt M, Schmieder A, et al. Matching physicians’ treatment recommendations to patients’ treatment preferences is associated with improvement in treatment satisfaction. J Eur Acad Dermatol Venereol. 2013;27(6):763–770. Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics. 2014;32(2):209–223. Kauf TL, Yang J-C, Kimball AB, et al. Psoriasis patients’ willingness to accept side-effect risks for improved treatment efficacy. J Dermatolog Treat. 2015;26(6):507–513. Kromer C, Schaarschmidt M-L, Schmieder A, et al. Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment. PLoS One. 2015;10(6):e0129120. Schaarschmidt M-L, Kromer C, Herr R, et al. Patient preferences for biologicals in psoriasis: top priority of safety for cardiovascular patients. PLoS One. 2015;10(12):e0144335. Rothery C, Bojke L, Richardson G, et al. A discrete choice experiment to explore patients’ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. Clin Rheumatol. 2016;35(12):2967–2974. Alcusky M, Lee S, Lau G, et al. Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis. Dermatol Ther (Heidelb). 2017;7(4):463–483. Eliasson L, Bewley AP, Mughal F, et al. Evaluation of psoriasis patients’ attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments . Patient Prefer Adherence. 2017;11:353–362. Fairchild AO, Reed SD, Johnson FR, et al. What is clearance worth? Patients’ stated risk tolerance for psoriasis treatments. J Dermatolog Treat. 2017;28(8):709–715. Guevara B, Gonzales N, Visitacion L. patient preference on psoriasis treatment in a Philippine Tertiary Hospital: a conjoint analysis: P127. J Eur Acad Dermatol Venereol. 2017;30:62. Gonzalez J, Johnson F, McAteer H, et al. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment. Br J Dermatol. 2017;176(3):777–785. Kromer C, Peitsch WK, Herr R, et al. Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability. J Dtsch Dermatol Ges. 2017;15(2):189–200. Bolt T, Kobayashi H, Mahlich J. Patient and physician preferences for therapy characteristics for psoriasis: a discrete choice experiment in Japan. PharmacoEconomics-open. 2018;3:255–264. Rigopoulos D, Ioannides D, Chaidemenos G, et al. Patient preference study for different characteristics of systemic psoriasis treatments (Protimisis). Dermatol Ther. 2018;31(3):e12592 Schaarschmidt M-L, Herr R, Gutknecht M, et al. Patients’ and physicians’ preferences for systemic psoriasis treatments: a nationwide comparative discrete choice experiment (PsoCompare). Acta Derm Venereol. 2018;98(2):200–205. Xu Y, Sudharshan L, Hsu M-A, et al. Patient preferences associated with therapies for psoriatic arthritis: a conjoint analysis. Am Health Drug Benefits. 2018;11(8):408. Feldman SR, Regnier SA, Chirilov A, et al. Patient-reported outcomes are important elements of psoriasis treatment decision making: a discrete choice experiment survey of dermatologists in the United States. J Am Acad Dermatol. 2019;80(6):1650–1657. Tada Y, Ishii K, Kimura J, et al. Patient preference for biologic treatments of psoriasis in Japan. J Dermatol. 2019;46(6):466–477.